Nexentis Technologies Inc.（NXTS）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

公司概況

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

產業: Agricultural Inputs
部門: Basic Materials
總部: IL
執行長: David Palach
上市以來: 2026年2月26日
僱員: 8

市場位置

日內區間

目前US$1.77，

US$1.70US$1.88

52週區間

目前US$1.77，

US$1.43US$58.80

開盤價: US$1.88
前收盤價: US$1.80
成交量: 7202; 0.01× 平均值
平均成交量: 132.23萬; 日均成交量
市值: 10.02萬 USD
貝塔: 1.86; 市場參考 1
50天平均值: US$3.2611; 低於平均水平-45.72%
200天平均值: US$8.2214; 低於平均水平-78.47%

財務數據

財務快照

估值與收益率

本益比（TTM）: -0.07×
股價淨值比（TTM）: 0.76×
股價營收比（TTM）: -1.52×
股息率: 0.00%

獲利能力和效率

毛利率: 268.18%
營業利益率: 17754.55%
淨利潤率: 24283.33%

財務健康

負債權益比: 0.22×
奧特曼 Z 分數: -5.31
皮奧特羅斯基 F 分數: 2 共 9 個

財報歷史與展望

最新每股收益結果: -25.96

EPS：實際值與預估值

近期已公布業績

實際值預估值

預估資料無法使用

營收：實際值與預估值

近期已公布業績

實際值預估值

預估資料無法使用

NXTS 訊息

globenewswire.com2026年7月28日

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE ® -driven discovery…

閱讀原始碼

globenewswire.com2026年7月7日

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative

MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery…

閱讀原始碼

globenewswire.com2026年6月29日

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to…

閱讀原始碼

globenewswire.com2026年6月22日

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

MITOLINE ® -Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

閱讀原始碼

globenewswire.com2026年6月17日

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to…

閱讀原始碼